KPTI News and Press, Karyopharm Therapeutics Inc. From 03/10/23

2023-03-10 13:20:19 ET Whether you’re trading penny stocks or higher-priced shares of larger companies, there’s no denying that new and more frequent trends have come to light. Thanks to the huge move in “Ape stocks” during the pandemic, traders are becoming ...

Karyopharm to Participate at Barclays Global Healthcare Conference PR Newswire NEWTON, Mass. , March 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced ...

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least...

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q4 2022 Earnings Call Feb 15, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q4 2022 Earnings Call Transcript

Karyopharm Therapeutics, Inc. (KPTI) Q4 2022 Earnings Conference Call February 15, 2023, 08:00 ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Me...

Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q4 GAAP EPS of -$0.43 misses by $0.09 . Revenue of $33.6M (-73.4% Y/Y) misses by $0.14M . Cash, cash equivalents, restricted cash and investments as of December 31, 2022 totaled $279.7 million, compared to $235.6 ...

Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress PR Newswire -- Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company's Gu...

Karyopharm Therapeutics ( NASDAQ: KPTI ) is scheduled to announce Q4 earnings results on Wednesday, February 15th, before market open. The consensus EPS Estimate is -$0.36 (vs. $0.46 last year) and the consensus Revenue Estimate is $33.74M (vs. $126.2M last year). Over the las...

Karyopharm to Present at SVB Securities Global Biopharma Conference PR Newswire NEWTON, Mass. , Feb. 9, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced ...

Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 PR Newswire -- Conference Call Scheduled for Wednesday, February 15, 2023 , at 8:00 a.m. ET -- NEWTON, Mass. , Feb. 8, 2023 /PRNewswire/ -- Karyopharm Th...